Accropeutics has developed a robust pipeline focusing on inflammation, fibrosis, autoimmune diseases and cancer
| Asset | Rights | Indication | Discovery | Pre-Clinical | IND | Phase l | Phase lb/ll | Phase Ill |
|---|---|---|---|---|---|---|---|---|
|
AC-101 Learn more |
Global | IBD |
|
|||||
| Global | Undisclosed autoimmune indication |
|
||||||
|
AC-201 Learn more |
Global(Excluding Greater China) | PsO |
|
|||||
| Global(Excluding Greater China) | NIU |
|
||||||
|
AC-003 Learn more |
Global | aGVHD |
|
|||||
| Global | IPF |
|
||||||
|
Confidential Targets |
Global | RA, AD, HS |
|
|||||
|
Confidential Targets |
Global | Asthma, COPD |
|
Copyright 2020.Accro Bioscience(Suzhou)Limited 苏ICP备20039637号 
苏公网安备32059002007536号
